文献速递其他结缔组织病自身炎症与 IgG4 相关病

专家视角:Castleman病的诊断与治疗

Expert Perspective: Diagnosis and Treatment of Castleman Disease.
PubMed 文献 · Arthritis Rheumatol · 2025-08-29

Castleman病是风湿科医生的重大诊断挑战,分为单中心型与多中心型,后者可与浆细胞肿瘤或HHV-8感染相关,但超过半数病例为特发性。特发性多中心型Castleman病(iMCD)可分为TAFRO型、IPL型及非特指型三种亚型,均以IL-6等细胞因子过多为驱动。所有iMCD亚型的一线治疗均为IL-6拮抗剂司妥昔单抗,难治性患者有多种治疗选择,建议参考治疗指南并咨询Castleman病专长中心。

要点

  • iMCD-TAFRO以快速起病的细胞因子风暴、严重炎症、全身水肿、血小板减少和小体积淋巴结肿大为特征。
  • iMCD-IPL表现为亚急性或慢性淋巴结肿大、炎症性贫血和多克隆性高丙种球蛋白血症,常伴血清及淋巴结组织IgG4升高。
  • 所有iMCD亚型的一线治疗为IL-6拮抗剂司妥昔单抗。

核心结论

  • Castleman病是风湿科医生的重大诊断挑战,单中心型与多中心型均可出现与其他免疫介导疾病重叠的广泛症状。
  • iMCD常表现为诊断谜题,症状异质,可分为TAFRO、IPL和NOS三种亚型,均以IL-6等细胞因子过多为驱动。
  • 所有iMCD亚型的一线治疗为IL-6拮抗剂司妥昔单抗,难治性患者有多种治疗选择。

研究设计与样本

  • 本文为专家视角综述,未报告系统检索范围与样本量。

主要发现

  • 单中心型Castleman病累及一个肿大淋巴结区域,多中心型累及多个肿大淋巴结区域。
  • MCD可与浆细胞肿瘤所致细胞因子过多相关(MCD-POEMS),或与未控制的人疱疹病毒8型感染相关(HHV-8阳性MCD),但超过半数病例为特发性。
  • iMCD-TAFRO以快速起病的细胞因子风暴伴严重炎症、全身水肿、血小板减少和小体积淋巴结肿大为特征,类似噬血细胞性淋巴组织细胞增生症或脓毒症。
  • iMCD-IPL表现为亚急性或慢性淋巴结肿大、炎症性贫血和多克隆性高丙种球蛋白血症,常伴血清及淋巴结组织IgG4升高,难以与IgG4相关病和组织细胞疾病鉴别。
  • 不符合TAFRO或IPL标准的iMCD为iMCD-NOS,常模仿惰性淋巴瘤或自身免疫病。

关键数值与推荐

  • iMCD-TAFRO的 hallmark 为快速起病细胞因子风暴、严重炎症、全身水肿、血小板减少和小体积淋巴结肿大。
  • iMCD-IPL常伴血清及淋巴结组织IgG4升高。
  • 所有iMCD亚型的一线治疗为司妥昔单抗(IL-6拮抗剂)。

临床怎么用

  • 自身免疫病、淋巴瘤和感染患者的反应性淋巴结可出现Castleman样改变,组织学发现必须结合临床和实验室检查以准确诊断iMCD。
  • Castleman病的治疗可分为免疫调节剂(如糖皮质激素、细胞因子抑制剂和西罗莫司)、抗淋巴瘤治疗(如利妥昔单抗、细胞毒化疗和BTK抑制剂)及抗骨髓瘤治疗(如沙利度胺和硼替佐米)三类。
  • 难治性患者有多种治疗选择,建议参考治疗指南并咨询具有Castleman病专长的中心。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune-mediated conditions. MCD can be associated with excessive cytokine production due to a plasma cell neoplasm (MCD-polyneuropathy, organomegaly, endocrinopathy, monoclonal paraprotein, skin changes) or uncontrolled human herpesvirus-8 infection (HHV-8) (HHV-8-positive MCD), but more than half of cases are idiopathic. Although they are all driven by excessive cytokines such as interleukin-6 (IL-6), patients with idiopathic MCD (iMCD) often present as a diagnostic mystery with heterogeneous symptomatology that can be classified into three subtypes. The three subtypes are iMCD-thrombocytopenia, anasarca, fever, renal dysfunction/reticulin fibrosis, organomegaly (TAFRO); iMCD-idiopathic plasmacytic lymphadenopathy (IPL); and iMCD-not otherwise specified (NOS). Rapid onset cytokine storm with severe inflammation, anasarca, thrombocytopenia, and small volume lymphadenopathy, similar to hemophagocytic lymphohistiocytosis or sepsis, are the hallmarks of iMCD-TAFRO. Patients with iMCD-IPL present with subacute or chronic lymphadenopathy, anemia of inflammation, and polyclonal hypergammaglobulinemia, often with increased IgG4 in serum and lymph node tissue; these cases can be difficult to distinguish from IgG4-related disease and histiocyte disorders. Those who have iMCD not meeting criteria for TAFRO or IPL have iMCD-NOS, which often mimics indolent lymphoma or autoimmune conditions. Patients with autoimmune disease, lymphoma, and infections can experience Castleman-like changes in reactive lymph nodes, and thus histologic findings must be combined with clinical and laboratory findings to accurately diagnose iMCD. Broadly speaking, treatments for CD can be considered in three categories: immunomodulators such as glucocorticoids, cytokine inhibitors, and sirolimus; antilymphoma therapies such as rituximab, cytotoxic chemotherapy, and BTK inhibitors; and antimyeloma therapies such as thalidomide and bortezomib. The first-line therapy for all subtypes of iMCD is siltuximab, an IL-6 antagonist. Patients with refractory disease have numerous treatment options and consulting treatment guidelines as well as consultation with a center with expertise in CD are recommended.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Chen LYC, Zhang L, Fajgenbaum DC, et al. Expert Perspective: Diagnosis and Treatment of Castleman Disease. Arthritis Rheumatol. 2025. PMID: 40457814. doi:10.1002/art.43269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。